Study guide
3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy
Australian Dental Council ADC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Examination Overview
1.1 ADC Written Examination Structure, Scoring Clusters & Australian Practice Context 1.2 Clinical Scenario Reasoning & Australian Therapeutic Guidelines Alignment
2 Chapter 2: Restorative Dentistry & Fixed Prosthodontics
2.1 Minimal Intervention Dentistry, Caries Risk & Lesion Management 2.2 Direct Restorative Materials, Resin Composites & Dental Amalgam 2.3 Indirect Restorations, Crown Preparation, Veneers & Onlays 2.4 Dental Adhesion, Etch-and-Rinse vs Self-Etch Systems & Hybrid Layer 2.5 Diagnosis & Management of Tooth Wear (Erosion, Attrition, Abrasion, Abfraction)
3 Chapter 3: Dental Pharmacology & Therapeutic Guidelines
3.1 Local Anaesthetic Agents, Vasoconstrictors & Injection Techniques 3.2 Dental Analgesia Protocols, NSAIDs, Paracetamol & Opioid Stewardship 3.3 Dental Antibiotic Prescribing, Prophylaxis & Therapeutic Guidelines 3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy 3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management
4 Chapter 4: General Medicine & Medically Compromised Patients
4.1 Dental Office Medical Emergencies, Anaphylaxis & Resuscitation Protocols 4.2 Management of Patients with Cardiovascular, Respiratory & Renal Diseases 4.3 Special Needs Dentistry, Geriatric Care & Dental Management in Pregnancy 4.4 Infective Endocarditis Prophylaxis & Cardiac Risk Assessment
5 Chapter 5: Oral Medicine & Oral Pathology
5.1 Ulcerative, Vesiculobullous & Immune-Mediated Oral Mucosal Diseases 5.2 Oral Potentially Malignant Disorders (OPMDs) & Oral Cancer Screening 5.3 Salivary Gland Disorders, Sialadenitis & Cysts of the Jaws 5.4 Oral Biopsy Indications, Diagnostic Pathways & Specialist Referral
6 Chapter 6: Endodontics
6.1 Pulpal and Periapical Diagnostic Classification & Diagnostic Testing 6.2 Canal Instrumentation, Working Length & Irrigation Protocols 6.3 Root Canal Obturation, Endodontic Retreatment & Failure Analysis 6.4 Endodontic Management of Traumatic Dental Injuries & Vital Pulp Therapy
7 Chapter 7: Oral Surgery
7.1 Surgical & Simple Exodontia Techniques & Intraoperative Complications 7.2 Assessment & Surgical Management of Impacted Third Molars 7.3 Oroantral Communication, Displacement & Trigeminal Nerve Injury Prevention 7.4 Management of Spreading Odontogenic Infections & Fascial Space Abscesses
8 Chapter 8: Paediatric Dentistry & Orthodontics
8.1 Primary Tooth Pulpotomy, Pulpectomy & Stainless Steel Crown Restoration 8.2 Early Childhood Caries, Space Maintenance & Traumatic Primary Dentition 8.3 Malocclusion Classification, Etiology & Interceptive Orthodontic Management 8.4 Non-Pharmacological Behaviour Guidance, Child Protection & Consent
9 Chapter 9: Periodontics
9.1 2018 Periodontal Staging, Grading & Risk Factor Assessment 9.2 Subgingival Debridement, Plaque Control & Antimicrobial Adjuncts 9.3 Periodontal Surgical Flaps, Regenerative Therapy & Furcation Management 9.4 Supportive Periodontal Care, Maintenance Protocols & Risk Re-evaluation
10 Chapter 10: Preventive Dentistry
10.1 Caries Risk Assessment Models (CAMBRA) & Personalised Prevention 10.2 Fluoride Mechanisms, Topical Applications & Community Fluoridation 10.3 Dietary Counselling, Stephan Curve Dynamics & Erosion Prevention 10.4 Pit and Fissure Sealants, Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP)
11 Chapter 11: Dental Emergencies
11.1 Emergency Management of Severe Odontogenic Pain & Acute Irreversible Pulpitis 11.2 Acute Management of Avulsed, Luxated & Fractured Permanent Teeth 11.3 Diagnosis, Differentiation & Treatment of Cracked Tooth Syndrome 11.4 Emergency Management of Post-Extraction Hemorrhage & Acute Abscesses
12 Chapter 12: Pain & Behaviour Management
12.1 Assessment & Management of Dental Anxiety, Phobia & Dental Fear 12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines 12.3 Diagnosis & Management of Temporomandibular Disorders & Chronic Facial Pain 12.4 Informed Consent, Patient Autonomy, Ethics & Professional Boundaries
13 Chapter 13: Removable Prosthodontics
13.1 Complete Denture Design, Impression Techniques & Maxillomandibular Relations 13.2 Removable Partial Denture Design, Surveying, Clasping & RPI System 13.3 Post-Insertion Problems, Sore Spots, Relining & Rebase Procedures 13.4 Denture Stomatitis, Tissue Conditioning & Pre-Prosthetic Surgery
14 Chapter 14: Dental Radiography & Imaging
14.1 Radiation Physics, ALARA Principles, Shielding & Dose Reduction 14.2 Intraoral Radiographic Techniques, Positioning & Geometry 14.3 Radiographic Interpretation, Normal Anatomical Landmarks & Artifacts
15 Chapter 15: Infection Prevention & Control
15.1 Standard & Transmission-Based Precautions in Dental Practice 15.2 Instrument Reprocessing, Autoclaving & Sterilisation Monitoring 15.3 Dental Unit Waterlines, Waste Management & Occupational Exposure Protocols
16 Chapter 16: Dental Implants & Peri-Implant Diseases
16.1 Patient Selection, Bone Density, Anatomic Constraints & Prosthetic Planning 16.2 Peri-Implant Anatomy, Hygiene Protocols & Maintenance Monitoring 16.3 Diagnosis, Risk Factors & Management of Peri-Implant Diseases
3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy
Key Takeaways Explain This Topic AI
Interrupting anticoagulant or antiplatelet therapy for dental procedures carries a significant risk of life-threatening thromboembolic events (stroke, myocardial infarction).
Minor oral surgery (1-3 extractions, periodontal surgery) can safely proceed without stopping antiplatelet agents (aspirin, clopidogrel) or Direct Oral Anticoagulants (DOACs).
For patients on Warfarin, an International Normalised Ratio (INR) must be checked within 24 hours prior to surgery; procedures can safely proceed if the INR is <= 3.5.
Direct Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) should be timed so that minor oral surgery is performed at trough drug levels (just before the next scheduled dose).
Local haemostatic measures (tranexamic acid 4.8% mouthwash, oxidized cellulose/gelatin sponges, sutures, pressure) are essential to control local intraoral bleeding.
Last updated: August 2026
3.4 Management of Patients on Anticoagulants & Antiplatelet Therapy
Managing dental patients taking antithrombotic medications requires balancing the risk of perioperative oral bleeding against the potentially catastrophic risk of thromboembolism (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction) if medications are temporarily discontinued. Current Australian clinical guidelines strongly support continuing antithrombotic therapy for minor oral surgical procedures while employing local haemostatic measures.
Haemostasis & Thromboembolic Risk Assessment
Haemostasis involves vascular constriction, primary platelet plug formation (primary haemostasis), and secondary activation of the coagulation cascade yielding a stable fibrin clot (secondary haemostasis). +---------------------------------------------------------------------------------------------------+
- | MECHANICAL HAEMOSTASIS PATHWAY |
- | |
- | Vascular Injury ===> Platelet Adhesion & Activation ===> Coagulation Cascade Activation |
- | (Target of Antiplatelets) (Target of Anticoagulants) |
- | || || |
- | / / |
- | Primary Platelet Plug Fibrin Mesh Formation |
- +---------------------------------------------------------------------------------------------------+
Discontinuing antithrombotic therapy prior to dental procedures creates a hypercoagulable rebound state. The risk of mortality or permanent disability from a thromboembolic stroke far outweighs the risk of localized, manageable oral bleeding.
Antiplatelet Therapies
Antiplatelet agents inhibit primary haemostasis by preventing platelet activation and aggregation.
Common Antiplatelet Medications
Aspirin : Irreversibly inhibits COX-1, blocking synthesis of Thromboxane A 2 A_2 A 2 ( T X A 2 TXA_2 TX A 2 ) for the lifespan of the platelet (~7-10 days).
P2Y12 Receptor Antagonists ( Clopidogrel , Prasugrel , Ticagrelor ): Inhibit ADP-induced platelet activation.
Dual Antiplatelet Therapy (DAPT) : Combination of Aspirin plus a P2Y12 inhibitor (e.g., Aspirin + Clopidogrel), commonly prescribed for 6-12 months following acute coronary syndrome or coronary stent insertion.
Antiplatelet Category Representative Drugs Dental Management Guidelines
Single Antiplatelet Aspirin (75-150 mg/day), Clopidogrel (75 mg/day) DO NOT INTERRUPT . Proceed with minor oral surgery using local haemostatic measures.
Dual Antiplatelet (DAPT) Aspirin + Clopidogrel / Ticagrelor DO NOT INTERRUPT . Discontinuation risks acute stent thrombosis. Limit surgical field size, operate carefully, and employ advanced local haemostasis.
Vitamin K Antagonists (Warfarin)
Warfarin inhibits hepatic vitamin K epoxide reductase, blocking gamma-carboxylation of clotting factors II, VII, IX, and X , as well as proteins C and S.
International Normalised Ratio (INR) Protocol
Warfarin monitoring relies on the INR, a standardized measure of prothrombin time.
Target Therapeutic Range : 2.0 to 3.0 for atrial fibrillation and DVT; 2.5 to 3.5 for mechanical heart valves.
Pre-Operative INR Testing : INR should be measured within 24 hours prior to minor oral surgery (or up to 72 hours if the patient has a stable INR history). INR CLINICAL THRESHOLDS FOR MINOR ORAL SURGERY:
-------------------------------------------------------------------------------------
- INR <= 4.0: PROCEED with minor oral surgery WITHOUT altering Warfarin dose.
- INR > 4.0: DO NOT OPERATE. Refer to prescribing medical practitioner for dose adjustment.
- ------------------------------------------------------------------------------------
- Minor Oral Surgery Definition: Extraction of 1 to 3 teeth, periodontal debridement,
minor soft tissue biopsy, or localized endodontic surgery.
Direct Oral Anticoagulants (DOACs / NOACs)
DOACs directly target specific coagulation factors, featuring rapid onset (1-4 hours), predictable pharmacokinetics, short elimination half-lives (12-15 hours), and no requirement for routine INR monitoring.
Classification & Properties of DOACs
Direct Thrombin (Factor IIa) Inhibitor : Dabigatran (Pradaxa).
Direct Factor Xa Inhibitors : Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban (Lixiana).
- Feature Warfarin DOACs (Rivaroxaban, Apixaban, Dabigatran)
- Target Factors II, VII, IX, X Direct Factor Xa or Factor IIa
- Onset Slow (3 – 5 days) Rapid (1 – 4 hours)
- Half-Life ( t 1 / 2 t_{1/2} t 1/2 ) 20 – 60 hours 12 – 15 hours
- Routine Monitoring Required (INR) Not required
- Reversal Agents Vitamin K, Prothrombin Complex Idarucizumab (Dabigatran), Andexanet alfa (Factor Xa)
- Dental Management Protocol for DOACs
Do NOT stop DOAC therapy for minor oral surgical procedures.
Timing Optimization : Perform procedures at trough plasma drug concentration :
For once-daily DOACs (e.g., Rivaroxaban taken in evening): Schedule appointment in the morning.
For twice-daily DOACs (e.g., Apixaban/Dabigatran taken morning and evening): Perform surgery just before the morning dose, or instruct patient to delay morning dose until haemostasis is verified post-surgery.
Schedule procedures early in the day and early in the week to allow management of any delayed oozing.
Perioperative Surgical Protocols & Local Haemostatic Measures
When treating patients on antithrombotic therapy, surgical execution and local haemostasis are vital.
Step-by-Step Local Haemostasis Protocol
Atraumatic Surgical Technique : Minimise tissue trauma, reflect full-thickness mucoperiosteal flaps cleanly, and smooth sharp alveolar bone crests.
Socket Dressing / Pack : Place an intra-socket haemostatic agent such as Oxidized Regenerated Cellulose (Surgicel) or Resorbable Gelatin Sponge (Gelfoam).
Suturing : Place 3-0 or 4-0 resorbable interrupted or cross-mattress sutures across socket margins under tension to adapt tissue flaps firmly.
Tranexamic Acid (TXA) Local Application : An antifibrinolytic agent that competitively inhibits plasminogen activation.
Topical Application : Saturate a sterile gauze pad with 5% Tranexamic Acid solution (or crush a 500 mg tablet in water) and apply firm pressure over surgical site for 20 minutes.
Post-Op Rinse : Prescribe 4.8% Tranexamic Acid mouthwash (10 mL rinse for 2 minutes, 4 times daily for 2 to 5 days). Instruct patient not to swallow .
Post-Operative Instructions : Avoid rinsing vigorously for 24 hours, avoid drinking through straws, avoid hot fluids, avoid smoking, and avoid strenuous exercise. +---------------------------------------------------------------------------------------------------+
- | LOCAL HAEMOSTATIC MEASURES MATRIX |
- | |
- | 1. Oxidized Cellulose / Gelatin Sponge in Socket |
- | 2. Resorbable Sutures to approximate mucosal margins |
- | 3. Firm pressure with 5% Tranexamic Acid soaked gauze (20 min) |
- | 4. Post-op 4.8% Tranexamic Acid mouthwash (qid for 2-5 days) |
- +---------------------------------------------------------------------------------------------------+
- Management of Post-Extraction Haemorrhage
If persistent intraoral bleeding occurs post-operatively:
Position patient upright, clear clots with suction, and identify exact source of bleeding (gingival margin vs intra-bony socket).
Administer local anaesthetic containing 1:80,000 adrenaline directly adjacent to bleeding site.
Debride excess fragile breakdown clot, repack socket with oxidized cellulose, resuture firmly, and re-apply pressure with Tranexamic Acid soaked gauze for 30 minutes.
Re-check systemic vital signs and blood pressure. If bleeding remains uncontrollable despite local measures, arrange emergency medical transfer for systemic reversal or factor administration.